To further confirm that these transcriptomic changes are evoked by DMD downregulation specifically in cancer cells rather than originating from DMD expression in the stromal or infiltrating immune cells present in tumor tissue samples, we conducted a two-class comparison analysis using the DepMap portal to identify DEGs between cell lines of the same tumor origin (carcinoma and sarcoma) but with low vs. high level of DMD gene expression. This evidence concerns the gene DMD and sarcoma.